

12:47 03 Sep 2020

Opyl shares jump after developing a software that predicts the likelihood of vaccine trial success

Opyl Ltd (ASX:OPL) has developed a software that uses artificial intelligence (AI) to make a probability of success prediction on the likelihood of a vaccine, drug, diagnostic or medical device succeeding in clinical trials.

Refining clinical trials

Previous studies demonstrated that on average only 13.8% of all drugs in phase 1 clinical trials eventually win approval from regulators and enter the market.

Typically, vaccines have a higher success rate (33.4%) than most other drugs, while cancer drugs have a far lower rate of success (3%).

The application of the Opyl software platform is to work with drug and device development companies to refine their clinical trial approaches to improve the outcomes of their clinical studies, which reduces costs and accelerates the timeline to get new treatments to patients.

Success prediction tool

Opyl chief executive officer Michelle Gallaher said: "We can see significant value in using the tool to inform clinical and treatment strategies, early procurement decision making and investments.

"The early outcome of this software trial, investigating the 475 registered COVID19 clinical trials related to vaccines or treatments, has delivered results that give us an indication of the power of the predictive platform in identifying the COVID19 trials, or any drug or device trial, with the greatest chance of success.

"Our approach is to use AI to not just predict the outcome, but to demonstrate that changing specific clinical trials variables can improve the probability of success.

"Our goal is to improve the efficiency, improve the application of research funding and ultimately the return on investment for scientists, clinicians, health technology developers and investors."

AI Platform

With hundreds of COVID19 clinical trials currently being undertaken around the globe, the company has available data for its AI platform.

The AI Platform uses current and historical global data and considers everything from the numbers of participants in each trial; the dropout rate from those trials; how long each trial will take; the end point for each trial relative to related studies, through to the mode of action such as type of protein or vector being employed in a program.

Next steps

Price: 0.13

Market Cap: \$4.8 m

1 Year Share Price Graph



Share Information

Code: OPL

Listing: ASX

52 week High Low
0.34 0.04

Sector: Online business & e-commerce

Website: opyl.ai

Company Synopsis:

Opyl (ASX:OPL) is a new generation company working at the intersection of artificial intelligence, social media and clinical trials.

action@proactiveinvestors.com.au

The next stage of the platform's development will involve increasing the data pool from additional clinical data sources and expanding the variables in order to further train the algorithm and refine the specificity and reliability.

Opyl is reaching out to those groups, such as governments and collaboration organisations that may have an interest in the findings from the COVID-19 work, as well as ongoing discussions with companies and partners on other applications of the technology.

Trading halt

Opyl shares have been granted a trading halt pending a response by Opyl to ASX queries.

The trading halt will remain in place until Opyl makes an announcement to the market or Monday, September 7, 2020, whichever is earlier.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).